Seres Therapeutics
Seres Therapeutics raises $113M Series E at $450M valuation
Quick Facts
Seres Therapeutics: Series E Funding Round
Seres Therapeutics has successfully raised $113M in Series E funding, reaching a valuation of $450M.
Company Overview
Microbiome therapeutic platform
Funding Details
The Series E round was led by Flagship Pioneering, with participation from Polaris Partners, Fidelity, Nestle Health Science, Takeda Ventures.
Company Information
- Headquarters: 200 Sidney Street, Cambridge, MA 02139
- Founded: 2010
- Employees: 250+
- Category: Biotech
Investment
Seres Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in Series E
- Polaris Partners: Verified investor in Series E
- Fidelity: Verified investor in Series E
- Nestle Health Science: Verified investor in Series E
- Takeda Ventures: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...